PRVA logo

PRVA PRVA

UnknownUnknownN/A📅 Scored April 7, 2026
Price at analysis: $21.96
Crucible Score
52.5
C
Quality × Value Composite
KQI — Quality
55.9
C
Fundamental Quality Index
KVI — Value
48.3
D+
Valuation Attractiveness Index
Crucible Verdict — PRVA

PRVA earns a mediocre C grade with concerning fundamentals despite decent growth momentum—the 74 Growth Profile score contrasts sharply with weak Financial Quality (45) and poor earnings execution (20% beat rate). PRVA trades near fair value at $22 versus $24 base case, but insider selling signals management lacks confidence. Growth potential remains intact if the company can fix operational execution and balance sheet issues.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality
44.8
Growth Profile
74.3
Moat Durability⚠
68.4
Management Effectiveness⚠
47.8
Diversification & Resilience⚠
42.0
Market Position
43.0
Weakest dimension: Diversification & Resilience (42.0)

◆ KVI Value Dimensions

DCF Margin of Safety
55.0
FCF Yield & Cash Returns
55.4
Relative Valuation
32.0
Growth-Adjusted Value
24.1
Historical Valuation
87.8
Macro Context
22.2

◆ DCF Valuation Scenarios

Bear Case
$14.52
Base Case
$24.18
Bull Case
$38.74
Price at Analysis
$21.96
ScenarioFair ValueRev CAGR (5yr)Terminal MarginWACC
🔴 Bear$14.526.0%2.5%9.2%
🟢 Base$24.1810.0%3.5%8.7%
🟢 Bull$38.7414.0%4.5%8.2%
Key Assumptions: PRVA is a healthcare information services company with very thin operating margins (1-2% in good years) and capital-light operations (capex <0.2% of revenue). Revenue grew from ~$966M to ~$2123M over 5 years (~17% CAGR) driven by organic growth and likely acquisitions, but margins remain razor-thin with EBITDA margins of ~2%. FCF conversion is strong relative to net income due to favorable working capital dynamics, but sustainable operating margins are assumed to remain in the 2.5-4.5% range given the pass-through nature of much of the revenue.

◆ Financial Snapshot

Profitability

Gross Margin9.6%
Operating Margin1.6%
Net Margin1.1%
ROIC2.6%
ROE-1.4%

Balance Sheet

Balance SheetCR: 1.60
Cash ConversionFCF/EPS: 6.95x
Capital IntensityCapex/Rev: 0.1%
Altman Z-Score4.54 (Safe)
Piotroski F-Score5/9 (Mixed)

Growth

Revenue CAGR21.7% CAGR
Earnings CAGR29.1% CAGR
Growth ConsistencyCV: 0.61
Segment Breadth6/6 growing (100%)
Quarterly TrendRev∆
Earnings CredibilityConsistent Misser

◆ Analyst Consensus & Leadership

Leadership & Governance

CEO Ownership5.7%
Insider ActivitySelling
Capital AllocationROIC 2.6% vs WACC 9.3%
Earnings Beat Rate20% (6/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+
MethodologyAll ScoresCrucible BriefsPerformance@KaladinCI

Analysis conducted April 7, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.

© 2026 Kaladin Capital Intelligence — Conviction Through Scrutiny